References

1. Kalow, W. Pharmacogenetics and personalised medicine. Fundam. Clin. Pharmacol. 16(5):337-342, 2002.

2. Lindpaintner, K. Pharmacogenetics and the future of medical practice. J. Mol. Med. 81(3): 141-153, 2003.

3. Meisel, C., Gerloff, T., Kirchheiner, J., et al. Implications of pharmacogenetics for individualizing drug treatment and for study design. J. Mol. Med. 81(3): 154-167, 2003.

4. Prows, C. A. and Prows, D. R. Medication selection by genotype: how genetics is changing drug prescribing and efficacy. Am. J. Nurs. 104(5):60-70, 2004.

5. Weinshilboum, R. Inheritance And drug response. N. Engl. J. Med. 348(6):529-537, 2003.

6. Kalow, W. and Gunn, D. R. Some statistical data on atypical cholinesterase of human serum. Ann. Hum. Genet 23:239-250, 1959.

7. Evans, D. A., Manley, K. A., and McKusick, V. A. Genetic control of isoniazid metabolism in man. Br. Med. J. 5197:485-491, 1960.

8. Kalow, W. Pharmacogenetics: Heredity and The Response To Drugs. W. B. Saunders, Philadelphia, PA, 1962.

9. Motulsky, A. G. Drug reactions enzymes, and biochemical genetics. J. Am. Med. Assoc. 165(7):835-837, 1957.

10. Motuslky. A. G. From pharmacogenetics and ecogenetics to phar-macogenomics. Med. Secoli 14(3):683-705, 2002.

11. Vogel, F. Modern problems of human genetics. Ergib. Kinderh. 12:52-125, 1959.

12. Anzenbacher, P. and Anzenbacherova, E. Cytochromes P450 and metabolism of xenobiotics. Cell. Mol. Life Sci. 58(5-6):737-747, 2001.

13. Wilkinson, G. R. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination, in Hardman, J. G. ed., Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, 2004, 3-29.

14. Cupp, M. J. and Tracy, T. S. Cytochrome P450: new nomenclature and clinical implications. Am. Fam. Physician 57(1): 107-116, 1998.

15. Ingelman-Sundberg, M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25(4): 193-200, 2004.

16. Ma, M. K., Woo, M. H., and Mcleod, H. L. Genetic basis of drug metabolism. Am. J. Health Syst. Pharm. 59(21):2061-2069, 2002.

17. Rushmore, T. H. and Kong, A. N. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr. Drug Metab. 3(5):481-490, 2002.

18. Brosen, K. and Gram, L. F. Clinical significance of the sparteine/debrisoquine Oxidation Polymorphism. Eu . J. Clin. Pharmacol. 36(6):537-547, 1989.

19. Eichelbaum, M. and Gross, A. S. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. Pharmacol. Ther. 46(3):377-394, 1990.

20. Zanger, U. M., Fischer, J., Raimundo, S., et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 11(7):573-585, 2001.

21. Daly, A. K., Brockmoller, J., Broly, F., et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics. 6(3): 193-201, 1996.

22. Meyer, U. A. and Zanger, U. M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37:269-296, 1997.

23. Chen, S., Chou, W. H., Blouin, R. A., et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin. Pharmacol. Ther. 60(5):522-534, 1996.

24. Griese, E. U., Zanger, U. M., Brudermanns, U., et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 8(1): 15-26, 1998.

25. Dalen, P., Dahl, M. L., Ruiz, M. L., Nordin, J., and Bertilsson, L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther. 63(4):444-452, 1998.

26. Dalen, P., Dahl, M. L., Eichelbaum, M., Bertilsson, L., and Wilkinson, G. R. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics 9(6):697-706, 1999.

27. Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjoqvist, F., and Ingelman-Sundberg, M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 1993; 90(24): 11, 825-11, 829, 1993.

28. Evans, W. E. and Mcleod, H. L. Pharmacogenomics—drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6): 538-549, 2003.

29. Ingelman-Sundberg, M., Oscarson, M., and Mclellan, R. A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends. Pharmacol. Sci. 20(8): 342-349, 1999.

30. Chalon, S. A., Desager, J. P., Desante, K. A., et al. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin. Pharmacol. Ther. 73(3): 178-191,2003.

31. Sauer, J. M., Ponsler G. D., Mattiuz, E. L., et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug. Metab. Dispos. 31(1): 98-107, 2003.

32. Witcher, J. W., Long, A., Smith, B., et al. Atomoxetine pharmacoki-netics in children and adolescents with attention deficit hyperactiv-ity disorder. J. Child. Adolesc. Psychopharmacol. 13(1): 53-63, 2003.

33. Remy, C. N., Metabolism of thiopyrimidines and thiopurines. S-Methylation with S-adenosylmethionine transmethylase and catab-olism in mammalian tissues. J. Biol. Chem. 238:1078-1084, 1963.

34. Woodson, L. C. and Weinshilboum, R. M., Human kidney thiop-urine methyltransferase. Purification and biochemical properties. Biochem Pharmacol 32(5):819-826, 1983.

35. Ferrajoli, A. and O'brien, S. M. Treatment of chronic lymphocytic leukemia. Semin. Oncol. 31(2 Suppl. 4):60-65, 2004.

36. Hia, C. P.,Yip, W. C., Tai, B. C., and Quek, S. C. Immunosuppressive therapy in acute myocarditis: an 18 year systematic review. Arch. Dis. Child. 89(6): 580-584, 2004.

37. Shapiro, R. Low toxicity immunosuppressive protocols in renal transplantation. Keio J. Med. 53(1): 18-22, 2004.

38. Ardizzone, S. and Porro, G. B. Comparative tolerability of therapies for ulcerative Colitis. Drug Safety 25(8):561-582, 2002.

39. de Jong, D. J., Derijks, L. J., Naber, A.H., Hooymans, P. M., and Mulder, C. J. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand. J. Gastroenterol.(239)69-72, 2003.

40. Coulthard, S. A. and Hall, A. G. Recent advances in the pharma-cogenomics of thiopurine methyltransferase. Pharmacogenom. J. 1(4):254-261, 2001.

41. Dubinsky, M. C., Lamothe, S., Yang, H. Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118(4):705-713, 2000.

42. Mcleod, H. L., Krynetski, E. Y., Relling, M. V., and Evans, W. E. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14(4): 567-572, 2000.

43. Relling, M. V., Hancock, M. L., Rivera, G. K., et al. Mercapto-purine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer. Inst. 91(23): 2001-2008, 1999.

44. Lennard, L. Therapeutic drug monitoring of cytotoxic drugs. Br. J. Clin. Pharmacol. 52 (Suppl. 1):75s-87s, 2001.

45. Marsh, S. and Mcleod, H. L. Cancer pharmacogenetics. B . J. Cancer 2004; 90(1):8-11, 2004.

46. Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., and Gottesman, M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:361-398, 1999.

47. Fromm, M. F., Kim, R. B., Stein, C. M., Wilkinson, G. R., and Roden, D. M. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine [see comments]. Circulation 99(4):552-557, 1999.

48. Kim, R. B., Fromm, M. F., Wandel, C., et al.. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101(2):289-294 ,1998.

49. Borst, P., Evers, R., Kool, M., and Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer. Inst. 92(16): 1295-1302, 2000.

50. Brinkmann, U., Roots, I., and Eichelbaum, M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov. Today 6(16):835-839, 2001.

51. Choo, E. F., Leake, B., Wandel, C., et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug. Metab. Dispos. 28(6):655-660, 2000.

52. Rao, V. V., Dahlheimer, J. L., Bardgett, M. E., et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. USA 96(7):3900-3905, 1999.

53. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84(21):7735-7738, 1987.

54. Hoffmeyer, S., Burk, O., von Richter, O., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97(7):3473-3478, 2000.

55. Drescher, S., Schaeffeler, E., Hitzl, M., et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofena-dine. B . J. Clin. Pharmacol. 53(5):526-534, 2002.

56. Kim, R. B., Leake, B. F., Choo, E. F., et.al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70(2): 189-199, 2001.

57. Fellay, J., Marzolini, C., Meaden, E. R., et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359(9300): 30-36, 2002.

58. Ioannidis, J. P., Ntzani, E. E., Trikalinos, T. A., and Contopoulos-Ioannidis D.G. Replication validity of genetic association studies. Nat. Genet. 29(3): 306-309, 2001.

59. Rabe, K. F. State of the art in beta2-agonist therapy: a safety review of long-acting agents. Int. J. Clin. Pract. 57(8):689-697, 2003.

60. Small, K. M., McGraw, D. W., and Liggett, S. B. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu. Rev. Pharmacol. Toxicol. 43:381-411, 2003.

61. Dishy, V., Sofowora, G. G., Xie, H. G., et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. 345(14): 1030-1035, 2001.

62. Martinez, F. D., Graves, P. E., Baldini, M., Solomon, S., and Erickson, R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 100(12):3184-3188, 1997.

63. Tan, S., Hall, I. P., Dewar, J., Dow, E., and Lipworth, B. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 350(9083): 995-999, 1997.

64. Tollman, P., Guy, P., Altshuler, J., Flanagan, A., and Steiner, M. A revolution in R&D; how genomics and genetics are transforming the biopharmaceutical industry. www.bcg.com, 2001

65. Nowlan, W. Human genetics. A rational view of insurance and genetic discrimination. Science 297(5579): 195-196, 2002.

66. Rothenberg, K. H. and Terry, S. F. Human genetics. Before it's too late-addressing fear of genetic information. Science 297(5579): 196-197, 2002.

67. Wertz, D. C. Ethical, social and legal issues in pharmacogenomics. Pharmacogenom. J. 3(4): 194-196, 2003.

68. Ingelman-Sundberg, M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med. 250(3): 186-200, 2001.

69. Evans, W. E. and Relling, M. V. Moving towards individualized medicine with pharmacogenomics. Nature 429(6990):464-468, 2004.

70. Slamon, D. J., Leyland-Jones, B., Shak, S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11):783-792, 2001.

71. Horton, J. Trastuzumab Use in breast cancer: clinical issues. Cancer Control 9(6):499-507, 2002.

72. Ross, J. S., Linette, G. P., Stec, J., et al. Breast cancer biomarkers and molecular medicine. Expert. Rev. Mol. Diagn. 3(5):573-585, 2003.

Applications of Molecular Diagnostics for Human Cancers vii

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment